Martin Palkovsky

Martin Palkovsky


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2024 in In Vivo
Verified
Journal Article
Open access
PDF file
MPMartin Palkovsky
Martin Palkovsky
NMNikol Modrackova
Nikol Modrackova
VNVera Neuzil-Bunesova
Vera Neuzil-Bunesova
MLMarian Liberko
Marian Liberko
RSRenata Soumarova
Renata Soumarova
Microbiome and radiotherapy represent bidirectionally interacting entities. The human microbiome has emerged as a pivotal modulator of the efficacy and toxicity of radiotherapy; however, a reciprocal effect of radiotherapy on microbiome composition alterations has also been observed. This review explores the relationship between the microbiome and extracranial solid tumors, particularly focusing on the bidirectional impact of radiotherapy on organ-specific microbiome. This article aims to provide a systematic review on the radiotherapy-induced microbial alteration in-field as well as in distant microbiomes. In this review, particular focus is directed to the oral and gut microbiome, its role in the development and progression of cancer, and how it is altered throughout radiotherapy. This review concludes with recommendations for future research, such as exploring microbiome modification to optimize radiotherapy-induced toxicities or enhance its anti-cancer effects.

3 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MPMartin Palkovsky
Martin Palkovsky
NMNikol Modrackova
Nikol Modrackova
VNVera Neuzil-Bunesova
Vera Neuzil-Bunesova
MLMarian Liberko
Marian Liberko
AHAlzbeta Hlodakova
Alzbeta Hlodakova
RSRenata Soumarová
Renata Soumarová
Despite decades of research, cancer remains a major global health problem

21 December 2025 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Open access
PDF file
MPMartin Palkovsky
Martin Palkovsky
AHAlzbeta Hlodakova
Alzbeta Hlodakova
JKJindrich Kopecky
Jindrich Kopecky
MPMarek Pasek
Marek Pasek
JSJiri Svec
Jiri Svec
RSRenata Soumarova
Renata Soumarova
Background: This study aims to evaluate the effectiveness of radiotherapy (RT) in stabilizing oligoprogressive disease (OPD) in melanoma patients undergoing immunotherapy. We hypothesize that RT’s efficacy in disease stabilization is influenced by factors such as dose, fractionation, metastatic burden, and the timing of OPD onset relative to immunotherapy initiation. Materials and methods: A retrospective observational study was conducted at two Czech university hospitals. Inclusion criteria encompassed metastatic melanoma patients undergoing immunotherapy with checkpoint inhibitors who developed OPD between January 2018 and May 2023. Exclusion criteria included central nervous system (CNS) involvement, discontinuation of systemic therapy during or after RT, and treatments other than immune checkpoint inhibitors. Patients were stratified based on RT initiation timing (< 6 months or >6 months from immunotherapy start) to assess primary and acquired resistance. 34 patients were included, with RT administered for extracranial OPD. Among these, local control was achieved in 21 patients. Results: Higher doses of RT [> 40 Gy the equivalent dose in 2 Gy fractions, (EQD2)] correlated with improved local control. Patients with fewer than five irradiated lesions experienced better progression-free survival (PFS) and overall survival (OS), however, the difference did not reach statistical significance. Multivariate analysis revealed that patients who received RT after > 6 months since initiation of immune checkpoint inhibitor (ICI) had significantly longer PFS. This study suggests, that RT is a viable option for stabilizing OPD in melanoma patients treated with immunotherapy, especially when administered later in the treatment course. Conclusions: Improved OS and PFS outcomes suggest that delayed OPD may indicate acquired resistance, which benefits from RT. Future studies should refine RT parameters and patient selection criteria to optimize clinical outcomes. Keywords: melanoma oligoprogression radiotherapy

30 January 2026 in Dermatology Practical & Conceptual
Verified
Journal Article
Open access
PDF file
MPMarek Pasek
Marek Pasek
PAPetr Arenberger
Petr Arenberger
VTVojtech Tretera
Vojtech Tretera
MPMartin Palkovsky
Martin Palkovsky
JVJana Vránová
Jana Vránová
MAMonika Arenbergerova
Monika Arenbergerova
MP has received honoraria or consulting fees from Bristol Myers Squibb (BMS), Merck Sharp and Dome (MSD). PA has received honoraria or consulting fees from BMS, MSD. VT has received honoraria or consulting fees from BMS. MP and JV declare no conflicts of interest. MA has received honoraria or consulting fees from BMS, MSD.